|Day's Range||0.3000 - 0.4400|
Both Hong Kong and Russia announced strict travel measures from mainland China, with the U.S. government expanding screening measures at key airports on Tuesday.
This company's business grew during the last recession, and it has one of the longest dividend growth streaks in the market Continue reading...
AbbVie stock fell on its $63 billion plan to acquire Botox-maker Allergan, which helps the pharmaceutical company diversify as Humira patents expire. So, is ABBV stock a buy right now?
Alector, Inc. (ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the dosing of the first Alzheimer’s disease patient in the Phase 1b portion of the INTERCEPT clinical study of AL003. AL003 is Alector’s second clinical-stage program targeting Alzheimer’s disease and is being developed in collaboration with its partner, AbbVie.
Shares of a handful of small and mid-sized biotechs that are working on vaccines for the Wuhan coronavirus are surging.
AbbVie stock rose Monday after the pharmaceutical company announced several divestments that will help it secure its $63 billion takeover of Allergan. Allergan stock also inched higher.
The selling was so intense in that period that it didn't matter if you were buying Verizon or Caterpillar or American Electric Power . There were so many people who left Wuhan, the epicenter, when they were still healthy and they are now coming down with the illness. It's pretty clear that the virus spreads from rapidly person to person, so rapidly that we are hearing lots of conspiracies about a bio lab in Wuhan that might have mistakenly discharged the coronavirus and it was not transmitted initially by animals to humans.
Shares of AbbVie Inc. were up 2% in trading on Monday morning after the drugmaker said Allergan , which it is in the process of acquiring, plans to divest two therapies. Allergan's stock is up 1%. It is selling brazikumab, an experimental Crohn's disease and ulcerative colitis treatment, to AstraZeneca and pancreatic treatment Zenpep to Nestlé. The divestitures are required for AbbVie to move forward with the $63 billion Allergan acquisition, which is expected to close this quarter. AbbVie's stock is up 3% over the last 52 weeks, while Allergan's stock has gained 18% during the same time frame. The Health Care Select Sector SPDR Fund has climbed 15% over the last year.
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
AbbVie Inc. (NYSE:ABBV) ("AbbVie") announced today the extension of the expiration date of the offers to exchange (each, an "Exchange Offer" and, collectively, the "Exchange Offers") any and all outstanding notes of certain series issued by Allergan Finance, LLC ("Allergan Finance"), Allergan, Inc. ("Allergan Inc"), Allergan Sales, LLC ("Allergan Sales") and Allergan Funding SCS ("Allergan Funding" and, together with Allergan Finance, Allergan Inc and Allergan Sales, "Allergan") (the "Allergan Notes") for new notes to be issued by AbbVie (the "AbbVie Notes") and the related consent solicitations (each, a "Consent Solicitation" and, collectively, the "Consent Solicitations") being made by AbbVie on behalf of Allergan to adopt certain amendments to each of the indentures (each, an "Allergan Indenture") governing the Allergan Notes. AbbVie hereby extends such expiration date from 5:00 p.m., New York City time, on January 31, 2020 to 5:00 p.m., New York City time, on February 28, 2020 (as the same may be further extended, the "Expiration Date").
AbbVie is rallying Monday as the company divests assets to get approval for its Allergan deal and as the company tries to help treat the coronavirus.
Regular readers of mine on Real Money know that I have been both an avid supporter and investor in AbbVie Inc. . It would be a positive for me if AbbVie would perform. There, now my personal bias is out in the open, let's talk in depth about AbbVie.
A mix of drugs made by AbbVie used to treat HIV patients with pneumonia is being tested in China as a possible antidote to the rapidly spreading coronavirus.
Stocks fall sharply Monday as investors weigh both the human and economic costs of the accelerating spread of the deadly coronavirus, which has killed 82 people and expanded to at least 10 different countries.
U.S. drugmaker AbbVie's $63 billion tie-up with Allergan is getting help from Nestle and AstraZeneca buying up products the Irish-domiciled company is shedding to placate regulators. AbbVie is swallowing Allergan to give it control of the lucrative wrinkle treatment Botox and to diversify a portfolio heavily dependent on its $19-billion-per-year arthritis drug Humira, the world's best-selling medicine that is advancing toward U.S. patent expiration. Swiss food group Nestle bulked up its medical nutrition business with Allergan's Zenpep, a product with 2018 sales of $237 million which treats people whose pancreases do not provide enough enzymes to digest fats, proteins and sugars.
AbbVie is the 'Stock of the Day' at Real Money. The company announced that they and Allergan have entered into definitive agreements to divest brazikumab (IL-23 inhibitor) and Zenpep (pancrelipase). Despite weakness in the broad market, ABBV is trading higher in the pre-market.
Allergan agrees to sell two of its drugs - Brazikumab and Zenpep - to Nestle and AstraZeneca to satisfy regulators ahead of its $63 billion merger with AbbVie.
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Allergan (NYSE: AGN), a leading global pharmaceutical company, today announced that Allergan has entered into definitive agreements to divest brazikumab (IL-23 inhibitor) and Zenpep (pancrelipase). These agreements are in conjunction with the ongoing regulatory approval process for AbbVie's acquisition of Allergan.
With earnings surprise in the cards, the healthcare sector is expected to witness substantial earnings growth of 4.4% in the fourth quarter, suggesting some room for potential upside for healthcare ETFs.